Press Releases

Press Releases
Date Title and Summary View
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG)today announced updated results from a retrospective analysis of a randomised, international phase III study of REVLIMID® (lenalidomide) for the treatment of patients with low/int-1 risk myelodysplast...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL) were presented at the 52nd Annual Meeting of the American ...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomised, double-blind study of continuous REVLIMID® ...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that updated data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the 52nd Annual Meeting of the American Society of Hematology....
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that its next IMiD® compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatm...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the 52nd A...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX®) in progressive or relapsed PTCL following prior ...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a rituximab-containing ...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma...
FirstPrevious ...
44
... NextLast
Add to Briefcase = add release to Briefcase